Shareholding disclosure

JPMorgan Chase & Co

Declared position

2.925%

Threshold

Crossed upwards

Timeline

Published

06.10.2015

Transaction

28.09.2015

Voting rights breakdown

Voting rights acquired2.925%
Voting rights sold0%
Below threshold0%

Notice details

CategorySingle shareholder
ExchangeXSWX

Notification ID

TAFA500039

Beneficial owner

JPMorgan Chase & Co

Declared address

JPMorgan Chase & Co., NY 10017/ New York

Relationship between JPMorgan Chase & Co. and the subsidiaries holding shares in Newron Pharmaceuticals SpA at 28 September 2015 JPMorgan Chase & Co. JPMorgan Asset Management Ho1dings Inc. (100%) JPMorgan Asset Management Internationa1 Limited (100%) JPMorgan Asset Management Holdings (UK) Limited (l00%) JPMorgan Asset Management (UK) Limited (100%) Business Addresses JPMorgan Chase & Co., 270 Park Avenue, New York, NY 10017,United States JPMorgan Asset Management Ho1dings Inc., 270 Park Avenue,New York, NY 10017, United States JPMorgan Asset Management International Limited, 60 Victoria Embankment, London EC4Y 0JP, United Kingdom JPMorgan Asset Management Holdings (UK) Limited, 60 Victoria Embankment, London EC4Y 0JP, United Kingdom JPMorgan Asset Management (UK) Limited, 60 Victoria Embankment, London EC4Y 0JP, United Kingdom Registered Addresses JPMorgan Chase & Co., c/o The Corporation Trust Company,1209 Orange Street, Wilmington, Delaware, DE 19081, United States JPMorgan Asset Management Holdings Inc., c/o The Corporation Trust Company, 1209 Orange Street,Wilmington,Delaware, DE 19081, United States JPMorgan Asset Management International Limited, 25 Bank Street, Canary Wharf, London E145JP, United Kingdom JPMorgan Asset Management Holdings (UK) Limited, 25 Bank Street, Canary Wharf, London E145JP, United Kingdom JPMorgan Asset Management (UK) Limited, 25 Bank Street,Canary Wharf, London E145JP, United Kingdom

These figures aggregate public disclosures. They are not investment advice.

Source: SIX Exchange Regulation

insider24.ch

Never miss a market signal again

Pro alertsEmail and Telegram after publication
Unlimited company trackingUnlimited watchlist with the Pro plan
Monday recapYour stocks' essentials at the open